[go: up one dir, main page]

WO1997030159A3 - Proteine recombinante contenant un fragment c-terminal de msp-1 tde plasmodium - Google Patents

Proteine recombinante contenant un fragment c-terminal de msp-1 tde plasmodium Download PDF

Info

Publication number
WO1997030159A3
WO1997030159A3 PCT/FR1997/000291 FR9700291W WO9730159A3 WO 1997030159 A3 WO1997030159 A3 WO 1997030159A3 FR 9700291 W FR9700291 W FR 9700291W WO 9730159 A3 WO9730159 A3 WO 9730159A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant protein
terminal fragment
protein containing
plasmodium
protein
Prior art date
Application number
PCT/FR1997/000291
Other languages
English (en)
Other versions
WO1997030159A2 (fr
Inventor
Shirley Longacre-Andre
Charles Roth
Faridabano Nato
John W Barnwell
Kamini Mendis
Original Assignee
Pasteur Institut
Univ New York
Longacre Andre Shirley
Charles Roth
Faridabano Nato
John W Barnwell
Kamini Mendis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Univ New York, Longacre Andre Shirley, Charles Roth, Faridabano Nato, John W Barnwell, Kamini Mendis filed Critical Pasteur Institut
Priority to CA002245727A priority Critical patent/CA2245727A1/fr
Priority to AU18842/97A priority patent/AU1884297A/en
Priority to KR1019980711022A priority patent/KR20000065265A/ko
Priority to EP97905213A priority patent/EP0880589A2/fr
Priority to JP09529058A priority patent/JP2000506381A/ja
Publication of WO1997030159A2 publication Critical patent/WO1997030159A2/fr
Publication of WO1997030159A3 publication Critical patent/WO1997030159A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une protéine recombinante, fabriquée dans un système à baculovirus, dont la séquence polypeptidique constitutive essentielle est celle d'un fragment C-terminal de 42 kilodaltons (p42) de la protéine 1 de surface (protéine MSP-1) de la forme mérozoïte d'un parasite du type Plasmodium, en particulier Plasmodium falciparum, infectieux pour l'Homme, ce fragment p42 étant particulièrement délété de sa région II et, le cas échéant, aussi de sa région III. Cette protéine recombinante est applicable à la production de vaccins contre la malaria.
PCT/FR1997/000291 1996-02-14 1997-02-14 Proteine recombinante contenant un fragment c-terminal de msp-1 tde plasmodium WO1997030159A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002245727A CA2245727A1 (fr) 1996-02-14 1997-02-14 Proteine recombinante contenant un fragment c-terminal de msp-1 tde plasmodium
AU18842/97A AU1884297A (en) 1996-02-14 1997-02-14 Recombinant protein containing a c-terminal fragment of plasmodium msp-1
KR1019980711022A KR20000065265A (ko) 1996-02-14 1997-02-14 말라리아 원충 msp-1의 c-말단 단편을 함유하는 재조합 단백질
EP97905213A EP0880589A2 (fr) 1996-02-14 1997-02-14 Proteine recombinante contenant un fragment c-terminal de msp-1 tde plasmodium
JP09529058A JP2000506381A (ja) 1996-02-14 1997-02-14 マラリア原虫ｍｓｐ―１のｃ末端断片を含む組換えタンパク質

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR96/01821 1996-02-14
FR9601821A FR2744723A1 (fr) 1996-02-14 1996-02-14 Proteine recombinante contenant un fragment c-terminal d'une proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques

Publications (2)

Publication Number Publication Date
WO1997030159A2 WO1997030159A2 (fr) 1997-08-21
WO1997030159A3 true WO1997030159A3 (fr) 1997-12-31

Family

ID=9489187

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1997/000291 WO1997030159A2 (fr) 1996-02-14 1997-02-14 Proteine recombinante contenant un fragment c-terminal de msp-1 tde plasmodium

Country Status (7)

Country Link
EP (1) EP0880589A2 (fr)
JP (1) JP2000506381A (fr)
KR (1) KR20000065265A (fr)
AU (1) AU1884297A (fr)
CA (1) CA2245727A1 (fr)
FR (1) FR2744723A1 (fr)
WO (1) WO1997030159A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2249097A (en) 1996-01-29 1997-08-20 Georgetown University Malaria vaccine based upon the addition of a msa1 peptide
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
CN1179048C (zh) 1997-10-20 2004-12-08 Gtc生物治疗学公司 修饰的MSP-1核酸序列以及增加细胞系统中mRNA水平和蛋白质表达的方法
US20030100106A1 (en) * 2000-02-08 2003-05-29 Chang Sandra P. Baculovirus produced Plasmodium falciparum vaccine
KR100373918B1 (ko) * 2000-02-17 2003-02-26 주식회사 엘지생명과학 말라리아의 효소 면역학적 측정방법 및 이에 사용되는진단시약
EP1409533A2 (fr) * 2001-01-26 2004-04-21 Walter Reed Army Institute of Research Vaccin a base de proteine-1/42 de merozoite i p.falciparum de recombinaison
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
US7595191B2 (en) 2001-01-26 2009-09-29 The United States Of America As Represented By The Secretary Of The Army Isolation and purification of P. falciparum merozoite protein-142 vaccine
CA2443947C (fr) * 2001-03-19 2012-01-31 Walter Reed Army Institute Of Research Vaccin recombinant p. vivax a base de proteine-1 p42 de merozoite
AU2003228441A1 (en) 2002-04-01 2003-10-20 The United States Of America As Represented By The Secretary Of The Army, Walter Reed Army Institute Of Research (Wrair) Recombinant p. falciparum merozoite protein-142 vaccine
WO2015055772A1 (fr) 2013-10-16 2015-04-23 Shirley Longacre Combinaison de protéines de surface de mérozoïte de plasmodium msp4 et 1 et utilisations correspondantes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154454A1 (fr) * 1984-02-22 1985-09-11 The Wellcome Foundation Limited Clonage d'ADN pour antigènes protozoiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154454A1 (fr) * 1984-02-22 1985-09-11 The Wellcome Foundation Limited Clonage d'ADN pour antigènes protozoiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LONGACRE, S. ET AL.: "Plasmodium vivax merozoite surface protein 1 C-terminal recombinant proteins in baculovirus", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 64, no. 2, 1 January 1994 (1994-01-01), pages 191 - 205, XP000603954 *
LONGACRE, S.: "The Plasmodium cynomolgi merozoite surface protein 1 C-terminal sequence and its homologies with other Plasmodium species", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 74, no. 1, 20 December 1995 (1995-12-20), pages 105 - 111, XP000603955 *

Also Published As

Publication number Publication date
FR2744723A1 (fr) 1997-08-14
AU1884297A (en) 1997-09-02
KR20000065265A (ko) 2000-11-06
CA2245727A1 (fr) 1997-08-21
WO1997030159A2 (fr) 1997-08-21
JP2000506381A (ja) 2000-05-30
EP0880589A2 (fr) 1998-12-02

Similar Documents

Publication Publication Date Title
WO1997030158A3 (fr) Proteine recombinante contenant un fragment c-terminal de msp-1 de plasmodium
WO1997030159A3 (fr) Proteine recombinante contenant un fragment c-terminal de msp-1 tde plasmodium
AUPM566794A0 (en) Process and product
PT82975A (en) Immunogenic peptide antigen corresponding to plasmodium vivax circumsporozoite protein and of vaccine against the malaria
WO2003016354A3 (fr) Anticorps de recombinaison anti-plasmodium falciparum
WO1995007353A3 (fr) Domaines de liaison provenant des proteines de liaison d'erythrocytes de plasmodium vivax et de plasmodium falciparum
WO1996040766A3 (fr) Domaines de liaison issus des proteines de liaison erythrocytaire derivees de plasmodium vivax et de plasmodium falciparum
NZ230817A (en) Polypeptide antigen corresponding to plasmodium falciparum circumsporozoite protein
DK200201741A (da) Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum
HUP0600028A2 (en) Nucleic acids encoding recombinant 56 and 82 kda antigens from gametocytes of eimeria maxima and their uses
AU2992489A (en) Method for producing recombinant protein derived from the circumsporozoite gene of plasmodium falciparum
BR9604989A (pt) Polipeptídeos modificados para imunogenicidade aperfeiçoada e processo de sua produção
IL90134A0 (en) Gene for encoding a human malaria vaccine antigen,malarial vaccines and pharmaceutical compositions
NZ513549A (en) Malaria vaccine
WO1995008631A3 (fr) Antigenes cibles d'anticorps arretant la transmission du parasite de la malaria
GR3029665T3 (en) 16 kDa SURFACE PROTEIN OF -i(P. FALCIPARUM).
AU5718794A (en) Recombinant nucleic acid, polypeptide material coded thereby and transmission blocking vaccine based thereon for controlling the malaria parasite (plasmodium falciparum )
DE60235044D1 (de) REKOMBINANTES, 250 kDa GROSSES ANTIGEN AUS SPOROZOITEN/MEROZOITEN VON EIMERIA MAXIMA CODIERENDE NUKLEINSÄUREN UND IHRE VERWENDUNGEN
EP0392820A3 (fr) Analogues de la protéine du plasmodium circumsporozoite sans séquences répétées
WO2000063245A3 (fr) Vaccin
AU1762092A (en) Circumsporozoite protein of plasmodium reichenowi and vaccine for human malaria
AU7163091A (en) Novel malarial sporozoite peptide antigens
AU3076592A (en) Malarial vaccine and peptides comprising human t-cell epitope of circumsporozoite protein of (p.vivax)
WO2001036587A3 (fr) Gene codant une proteine de surface de merozoite de plasmodium vivax
HK1067639A (en) Nucleic acids encoding a recombinant 250 kda antigen from sporozoites/merozoites of eimeria maxima and their uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP KP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2245727

Country of ref document: CA

Ref document number: 2245727

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997905213

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019980711022

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 97193042.2

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1997905213

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997905213

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019980711022

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019980711022

Country of ref document: KR